Rewiring glucose metabolism improves 5-FU efficacy in p53-deficient/KRAS(G12D) glycolytic colorectal tumors

Despite the fact that 5-fluorouracil (5-FU) is the backbone for chemotherapy in colorectal cancer (CRC), the response rates in patients is limited to 50%. The mechanisms underlying 5-FU toxicity are debated, limiting the development of strategies to improve its efficacy. How fundamental aspects of c...

Descripción completa

Detalles Bibliográficos
Autores principales: Ludikhuize, Marlies C., Gevers, Sira, Nguyen, Nguyen T. B., Meerlo, Maaike, Roudbari, S. Khadijeh Shafiei, Gulersonmez, M. Can, Stigter, Edwin C. A., Drost, Jarno, Clevers, Hans, Burgering, Boudewijn M. T., Rodríguez Colman, Maria J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622833/
https://www.ncbi.nlm.nih.gov/pubmed/36316440
http://dx.doi.org/10.1038/s42003-022-04055-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622833/
https://www.ncbi.nlm.nih.gov/pubmed/36316440
http://dx.doi.org/10.1038/s42003-022-04055-8

Ejemplares similares